This inventor holds 1 USPTO granted patent. Top assignee: Immusol, Incorporated. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998
Title: Tsvi Goldenberg: Innovator in Ribozyme Therapy
Introduction
Tsvi Goldenberg is a notable inventor based in La Jolla, California. He has made significant contributions to the field of medical therapies, particularly in the area of ribozyme technology. His work focuses on innovative solutions for vascular health, specifically targeting restenosis.
Latest Patents
Goldenberg holds a patent for "Ribozyme therapy for the inhibition of restenosis." This invention provides ribozymes and ribozyme delivery systems that are effective in inhibiting abnormal smooth muscle cell proliferation in vascular tissue. The patent also outlines methods for producing ribozymes and utilizing gene therapy with these ribozymes.
Career Highlights
Goldenberg is associated with Immusol, Incorporated, where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of vascular diseases, offering new hope for patients suffering from restenosis.
Collaborations
One of his notable collaborators is Richard Tritz, who works alongside him at Immusol, Incorporated. Their combined expertise contributes to the innovative approaches being developed in the field of ribozyme therapy.
Conclusion
Tsvi Goldenberg's contributions to ribozyme therapy exemplify the intersection of innovation and medical science. His work not only addresses critical health issues but also paves the way for future advancements in vascular treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile